GlassScriptPhysician profile
Amir Ali Faridi
NPI 1659319028
$53,989.72
in general payments reported to CMS, 2019-2025
64 companies · $8,119 in 2025
The $8,119 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $5,171 · 2021: $8,365 · 2022: $8,093 · 2023: $9,159 · 2024: $2,346 · 2025: $8,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $3,204 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,725 · Education: $521 · Long Term Medical Supply Or Device Loan: $283 · Travel and Lodging: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,631.00 |
| Food and Beverage | $3,204.09 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,725.00 |
| Education | $521.12 |
| Long Term Medical Supply Or Device Loan | $282.73 |
| Travel and Lodging | $259.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $9,026.75 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $6,347.53 | 2025 | |
| Pfizer INC. | $4,847.86 | 2019-2025 | |
| Deciphera Pharmaceuticals INC. | $4,531.15 | 2022 | |
| Janssen Biotech, INC. | $3,529.47 | 2019-2025 | Talvey, Tecvayli, Erleada |
| Kyowa Kirin, INC. | $3,203.64 | 2019 | |
| Gilead Sciences, INC. | $3,019.58 | 2021-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $2,464.99 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $2,251.73 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $1,771.86 | 2020-2025 | Imfinzi, Enhertu |
| Cti Biopharma Corp. | $1,748.79 | 2022-2023 | Vonjo |
| Seagen INC. | $1,701.42 | 2019-2023 | Adcetris |
| Epizyme, INC. | $1,329.99 | 2021-2022 | |
| Array Biopharma INC | $1,281.04 | 2021-2025 | Tukysa, Braftovi, Mektovi |
| Aveo Pharmaceuticals, INC. | $1,144.31 | 2021-2025 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,044.27 | 2019-2025 | Opdivo |
| Janssen Scientific Affairs, LLC | $1,010.00 | 2022 | |
| Emd Serono, INC. | $574.74 | 2020-2025 | |
| Astellas Pharma US INC | $522.03 | 2020-2025 | Vyloy, Xospata |
| Incyte Corporation | $453.16 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Glaxosmithkline, LLC. | $185.45 | 2020-2025 | Blenrep, Ojjaara |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Inari Medical, INC. | $150.27 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Daiichi Sankyo INC. | $140.31 | 2023-2025 | Enhertu |
| Genzyme Corporation | $121.26 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $92.35 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Abbvie INC. | $88.99 | 2024-2025 | |
| Tempus Ai, INC | $77.30 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $71.97 | 2021-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $67.64 | 2023-2025 | Fruzaqla, Alunbrig |
| Stemline Therapeutics INC. | $58.33 | 2024-2025 | Orserdu |
| Exelixis INC. | $57.76 | 2019-2023 | Cabometyx |
| Agios Pharmaceuticals, INC. | $55.95 | 2019-2025 | Pyrukynd |
| Beigene USA, INC. | $54.56 | 2022-2024 | Brukinsa |
| Servier Pharmaceuticals LLC | $53.43 | 2022 | |
| Lilly USA, LLC | $51.21 | 2023-2025 | Verzenio, Jaypirca |
| Geron Corporation | $50.47 | 2025 | Rytelo |
| Amgen INC. | $49.88 | 2020-2023 | Lumakras |
| Syndax Pharmaceuticals, INC. | $49.79 | 2025 | |
| Celgene Corporation | $45.65 | 2022-2025 | Reblozyl |
| Pharmaessentia USA Corporation | $43.29 | 2023-2025 | Besremi |
| Pharmacyclics LLC, An Abbvie Company | $38.38 | 2020-2022 | |
| Dova Pharmaceuticals | $35.01 | 2020 | |
| Medtronic, INC. | $32.38 | 2024 | Osteocool Rf Ablation System |
| Springworks Therapeutics, INC. | $29.39 | 2025 | Ogsiveo |
| Rigel Pharmaceuticals, INC. | $27.90 | 2023 | Rezlidhia, Tavalisse |
| Blueprint Medicines Corporation | $26.33 | 2021 | |
| Genentech USA, INC. | $25.58 | 2020-2025 | Tecentriq |
| G1 Therapeutics, INC. | $25.44 | 2023 | Cosela |
| Dendreon Pharmaceuticals LLC | $24.77 | 2025 | Provenge |
| Taiho Oncology, INC. | $24.52 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $24.11 | 2023 | Onivyde |
| Nuvation Bio INC. | $23.99 | 2025 | Ibtrozi |
| Genmab U.S., INC. | $23.96 | 2025 | Epkinly |
| Acrotech Biopharma INC. | $23.94 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $21.50 | 2025 | Givlaari |
| Verastem, INC. | $19.68 | 2019 | |
| Eisai INC. | $17.67 | 2024 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Faridi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.